Targeting p21 for diabetes: Another choice of senotherapy.
Level V
Where this comes from
- Record sourced from PubMed, PMID 34986338.
- Also identified by DOI 10.1016/j.cmet.2021.12.008.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Senotherapy, the elimination of senescent cells, is a cutting-edge treatment for aging-related and lifestyle diseases. In this issue of Cell Metabolism, Wang et al. report that p21<sup>Cip1</sup> highly expressing cells, which represent a senescent cell population, occur in the adipose tissue during obesity. Targeting them genetically or pharmacologically attenuates insulin resistance, suggesting a possible therapeutic approach to treat the metabolic complications of obesity.
Medical subject headings
- Diabetes Mellitus
- Insulin Resistance